<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841538</url>
  </required_header>
  <id_info>
    <org_study_id>ES101-2001</org_study_id>
    <nct_id>NCT04841538</nct_id>
  </id_info>
  <brief_title>A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors</brief_title>
  <official_title>An Open-label, Multicenter, Multicohort Phase 1b/2 Clinical Trial of ES101 in Patients With Advanced Malignant Thoracic Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elpiscience Biopharma, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elpiscience Biopharma, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, RP2D and PK/pharmacodynamic profile of&#xD;
      ES101 monotherapy in patients with advanced NSCLC and to further evaluate the antitumor&#xD;
      efficacy of ES101 in advanced malignant thoracic tumors, including NSCLC and SCLC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: Frequency and severity of adverse events of ES101</measure>
    <time_frame>1-2 years</time_frame>
    <description>Adverse events will be assessed and assigned by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Recommended Phase 2 Dose (RP2D) of of ES101</measure>
    <time_frame>6 months</time_frame>
    <description>RP2D of ES101 will be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Objective response rate (ORR)</measure>
    <time_frame>2-3 years</time_frame>
    <description>Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of ES101</measure>
    <time_frame>2-4 years</time_frame>
    <description>Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of ES101</measure>
    <time_frame>2-4 years</time_frame>
    <description>Assess the relationship between ES101 exposure and efficacy/adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of ES101</measure>
    <time_frame>2-4 years</time_frame>
    <description>Frequency of anti-drug antibodies (ADA) against ES101 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic markers</measure>
    <time_frame>2-4 years</time_frame>
    <description>Assess PD-L1 receptor occupancy and cytokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1 expression</measure>
    <time_frame>2-4 years</time_frame>
    <description>Assess PD-L1 expression status of tumor tissues</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Thoracic Tumors</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ES101 is administered via intravenous infusion, 0.3mg/kg，once every 14 days, every 28 days as a treatment cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ES101 is administered via intravenous infusion, 1mg/kg，once every 14 days, every 28 days as a treatment cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ES101</intervention_name>
    <description>The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent form.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.&#xD;
&#xD;
          -  At least one measurable lesion is required (RECIST v1.1)&#xD;
&#xD;
          -  Phase 1b: Subjects with pathologically or cytologically confirmed recurrent or&#xD;
             metastatic NSCLC without known EGFR mutation and ALK and ROS1 gene rearrangements.&#xD;
&#xD;
          -  Phase II: Subjects with pathologically or cytologically confirmed recurrent or&#xD;
             metastatic malignant thoracic tumours who have received 1-2 lines of systemic&#xD;
             anti-tumour therapy, including platinum regimens, and have failed, including at least&#xD;
             2 cycles of chemotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to 4-1BB agonists.&#xD;
&#xD;
          -  Receipt of any anticancer investigational product or any approved drug(s) or&#xD;
             biological products (except hormone-replacement therapy, testosterone or oral&#xD;
             contraceptives) within 4 weeks prior to the first dose of study drug. Previous&#xD;
             exposure to oral fluorouracils or small molecular targeted drugs require a minimum&#xD;
             washout period of 2 weeks or 5 half-lives prior to the first dose of study drug&#xD;
             (whichever is longer). Previous exposure to mitomycin C or nitrosourea requires a&#xD;
             minimum washout period of 6 weeks prior to the first dose of study drug.&#xD;
&#xD;
          -  Receipt of PD-L1 therapy within 24 weeks prior to the first dose of study drug.&#xD;
&#xD;
          -  Known allergies to CHO-produced antibodies, which in the opinion of the Investigator&#xD;
             suggests an increased potential for an adverse hypersensitivity to ES101.&#xD;
&#xD;
          -  Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation&#xD;
             of prior immunotherapy. Some exceptions as defined per protocol apply.&#xD;
&#xD;
          -  Subject has not recovered from all AEs of previous anticancer therapies to baseline or&#xD;
             ≤ Grade 1 per CTCAE v5.0 before teh first dose of study drug. Certain exceptions as&#xD;
             defined in protocol apply.&#xD;
&#xD;
          -  Active autoimmune disease or documented history of autoimmune disease that required&#xD;
             systemic steroids or other immunosuppressive medications. Certain exceptions as&#xD;
             defined in protocol apply.&#xD;
&#xD;
          -  Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or&#xD;
             pneumonitis requiring treatment with steroids or other immunosuppressive medications.&#xD;
&#xD;
          -  Systemic anti-infectious drug treatments within 4 weeks prior to the first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Pregnant or nursing females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>He Yafeng</last_name>
    <phone>86 021-50651310</phone>
    <email>clinical-operation@elpiscience.com</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ES101</keyword>
  <keyword>INBRX-105</keyword>
  <keyword>PD-L1</keyword>
  <keyword>4-1BB</keyword>
  <keyword>PD-L1×4-1BB</keyword>
  <keyword>PDL1</keyword>
  <keyword>41BB</keyword>
  <keyword>Thoracic Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Thoracic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

